Preclinical Discovery
Enter IND and Phase 1 studies with validated targets and mechanistic insights predictive of therapeutic response.
Target Identification
Profile over 1T marker combinations to identify novel targets across the innate and adaptive immune system.
Mechanism of Action
Understand the complex network of immune cell interactions associated with your target.
Target Validation
Select an approach that maximizes therapeutic response to facilitate entry into IND-study.
Target Identification
Don’t limit yourself to a handful of subsets, expand your immune profiling capabilities to identify which aspects of biology your candidate is hitting.
Mechanism of Action
Before Teiko.bio
The assumption is CD8 T cells need to be targeted directly. However, this leads to therapy failure.
With Teiko.bio
Immune profiling reveals the actual issue is upstream, with dendritic cells not being activated.
After Teiko.bio
Upstream anti-CD40 therapy activates dendritic cells to create therapy success.
Target Validation
- Identify approaches that maximize therapeutic effect
- Which combination strategies to pursue
- Validate a therapeutic approach and target to enter for IND-stage study